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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.018Failure of ﬁbrotic liver to regenerate after resection limits therapeutic options and increases demand for
liver transplantation, representing a signiﬁcant clinical problem. The mechanism underlying regener-
ative failure in ﬁbrosis is poorly understood. Seventy percent partial hepatectomy (PHx) was performed
in C57Bl/6 mice with or without carbon tetrachloride (CCl4)-induced liver ﬁbrosis. Liver function and
regeneration was monitored at 1 to 14 days thereafter by assessing liver mass, alanine aminotransferase
(ALT), mRNA expression, and histology. Progenitor (oval) cell mitogen tumor necrosis factor-like weak
inducer of apoptosis (TWEAK) and TWEAK-neutralizing antibody were used to manipulate progenitor cell
proliferation in vivo. In ﬁbrotic liver, hepatocytes failed to replicate efﬁciently after PHx. Fibrotic livers
showed late (day 5) peak of serum ALT (3542  355 IU/L compared to 93  65 IU/L in nonﬁbrotic
livers), which coincided with progenitor cell expansion, increase in proﬁbrogenic gene expression and
de novo collagen deposition. In ﬁbrotic mice, inhibition of progenitor activation using TWEAK-
neutralizing antibody after PHx resulted in strongly down-regulated proﬁbrogenic mRNA, reduced
serum ALT levels and improved regeneration. Failure of hepatocyte-mediated regeneration in ﬁbrotic
liver triggers activation of the progenitor (oval) cell compartment and a severe ﬁbrogenic response.
Inhibition of progenitor cell proliferation using anti-TWEAK antibody prevents ﬁbrogenic response and
augments ﬁbrotic liver regeneration. Targeting the ﬁbrogenic progenitor response represents a prom-
ising strategy to improve hepatectomy outcomes in patients with liver ﬁbrosis. (Am J Pathol 2013, 183:
182e194; http://dx.doi.org/10.1016/j.ajpath.2013.03.018)Supported in part by NIH grants R01GM088666-03 (L.E.O.) and NIH 1
R21 DK076873-01A1 (D.S.), a Julie Henry Fund grant (D.W.H.), and
departmental and unrestricted grants from Stromedix, Inc. (Y.P.).
Disclosures: L.B. is an employee of Biogen Idec, Inc., which holds
patents and pending patent applications in the United States and abroad on
TWEAK-related molecules, including U.S. Patent No. 7129061, 7109298,
7087725, 7695934, 7566769, and 8048422. Biogen Idec, Inc. provided
some of the research tools (TWEAK-Fc and anti-TWEAK antibody) used
in this study.The liver is the only organ that has the impressive ability to
regenerate after injury or surgical resection.1 Partial hepa-
tectomy (PHx) is the most commonly used model for
studying this unique capacity of the liver. After PHx, up to
95% of hepatocytes begin to replicate to compensate for the
lost tissue and, in mice, regeneration reaches a maximum of
30 to 60 hours.2 The remnant liver increases its volume until
the regenerated liver mass approaches the original volume.
This proliferation of hepatocytes is followed by proliferation
of biliary epithelial cells and sinusoidal cells, and full
restoration of hepatic architecture and function.1
The canals of Hering connect the terminal segment of the
biliary ductal system with parenchymal hepatocytes.3,4 Cells
residing in the canals of Hering, called oval cells because ofstigative Pathology.
.their morphology, function as adult hepatic stem cells. Oval
cells express both fetal hepatocyte and biliary cell markers
and have the ability to generate both hepatocytes and
cholangiocytes,5 thus considered to be bipotent progenitor
cells in adult liver.6
Progenitors and Fibrotic Liver RegenerationLiver regeneration can occur via two distinct pathways,
hepatocyte- and progenitor (oval) cell-mediated. After PHx
performed on the healthy liver, hepatocytes are the primary
replicating cells responsible for liver regeneration. Although
contribution of intrahepatic and extrahepatic (bone marrow)
stem cell was proposed, recent and carefully conducted cell
fate-tracing studies conﬁrm that normal liver regeneration
occurs via mature hepatocyte proliferation.7 Progenitor
(oval) cell activation leading to hepatocyte regeneration is
not observed during this process.2,7 On the other hand, oval
cell proliferation is prominent in some experimental models
of liver injury and carcinogenesis induced by Azo dyes,
choline deﬁcient and ethionine-containing diets, D-galac-
tosamine, acetylaminoﬂuorene, or CCl4 treatment.
8 When
hepatectomy is combined with inhibition of mature hepa-
tocyte replication, regeneration occurs primarily via the
proliferation of oval cells and their differentiation into
hepatocytes.2
The wound healing response is a series of cellular and
molecular events necessary for prompt tissue repair after injury.9
Chronic liver injury often results in hepatic ﬁbrosis, deﬁned
by excessive extracellular matrix deposition in periportal areas
or in the parenchyma that may progress to cirrhosis with
distortion of hepatic architecture, compromised function, and
life-threatening complications. Cirrhosis is common end-stage
pathology of chronic liver disease of numerous etiologies.
Although themechanisms that lead to theprogressionofﬁbrosis,
as well as the speciﬁc cells, mediators, and transcription factors
that contribute to ﬁbrosis progression are increasingly under-
stood,10 no clinically proven anti-ﬁbrotic treatment exists.11
Hepatic resection is rarely performed in patients with
liver cirrhosis, even of Child-Pugh grade A, due to poor
outcomes. It is clinically well known that in the setting of
advanced ﬁbrosis, liver regeneration is severely impaired,12
but a lack of mechanistic understanding of this phenomenon
has severely hampered efforts to improve ability of ﬁbrotic
liver to regenerate and permit resection in these patients. To
date, there is ample experimental literature focusing on liver
regeneration after PHx in normal livers, but ﬁbrotic liver
regeneration remains understudied. Here, we describe the
detailed characterization of a murine model of PHx of
ﬁbrotic liver, which permits further insights into molecular
mechanisms of regeneration in the context of ﬁbrotic liver
and importantly allows formal preclinical testing of poten-
tial regeneration enhancing agents. We demonstrate for the
ﬁrst time that therapeutic targeting of the proﬁbrogenic
progenitor (oval) cell response offers a novel approach by
which to improve regeneration in ﬁbrotic livers.
Materials and Methods
Animal Experiments
All animal experiments and procedures were reviewed and
approved by the Institutional Animal Care and Use Committee
at Beth Israel Deaconess Medical Center (Harvard MedicalThe American Journal of Pathology - ajp.amjpathol.orgSchool, Boston, MA; protocols #189-2006 and #158-2008).
C57BL/6 mice (6-week-old males) were purchased from the
Jackson Laboratory (Bar Harbor, ME) and used in experi-
ments after 1 week of acclimatization in the animal facility at
Beth Israel Deaconess Medical Center. CCl4 and mineral oil
were purchased from Sigma-Aldrich (St. Louis, MO). A 70%
PHx was performed 3 days after the last dose of CCl4
according to the standard procedure as previously described in
mice,13 with pre-established liver ﬁbrosis induced (nZ 86) or
without (n Z 144), described as follows. Brieﬂy, anesthesia
was induced by inhalation of isoﬂurane (2% v/v). After lapa-
rotomy, the left and median liver lobes were removed sepa-
rately, distal to 4-0 silk ties. Body weights and the survival of
each mouse were postoperatively recorded every day, and
mice were sacriﬁced at selected time points after surgery.
Hepatotoxin-Induced Mouse Liver Fibrosis Model
Liver ﬁbrosis was induced in C57Bl/6 mice (Jackson
Laboratories, Bar Harbor, ME), according to an optimized
escalating dose regimen of CCl4 in mineral oil by oral
gavage three times per week (Monday, Wednesday, and
Friday) for 6 weeks, as previously established.14 Nonﬁbrotic
controls received mineral oil as a vehicle only.
Model of Liver Regeneration after PHx
Mice were sacriﬁced at 1, 2, 3, 5, 10, and 14 days after PHx to
access liver regeneration parameters (n Z 10 to 21 per time
point), essentially as previously described.15 Body weights at
the time of sacriﬁce were measured, liver specimens and blood
samples were collected, and liver weights were recorded.
Resected liver tissues were immediately snap frozen in liquid
nitrogen and were used as preresection controls to be
compared to postresection parameters in each individual
mouse. In initial experiments, both mineral oil-treated mice
and untreated mice were used as normal controls (mineral oil-
treated mice out of total per time point: day 1, 4 of 10; day 2, 8
of 16; day 3, 2 of 10; day 10, 6 of 16; day 14, 3 of 10). Because
none of the general parameters differed among these control
groups, as related to liver regeneration [body weight change
after surgery, liver regeneration, hepatocyte proliferation, and
alanine aminotransferase (ALT)] (levels of ALT, data not
shown), the untreated mice were used as normal controls in all
subsequent experiments.
Manipulation of Progenitor (Oval) Cell Compartment
via the TWEAK Pathway
For progenitor (oval) cell inhibition experiments, mice were
dosed intraperitoneally with either 75 mg neutralizing antie
tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) monoclonal antibody (clone P2D10, Biogen
Idec, Cambridge, MA)16 or 75 mg isotype IgG (mouse
IgG2a, clone P1.17) generated from a commercial cell line
(ATCC, Manassas, VA).183
Kuramitsu et alOval cell proliferation was induced with recombinant
TWEAK-Fc fusion protein (TWEAK-Fc, 75mg permouse).16
All injections were made three times: on day 0 (4 hours after
surgery), on day 2, and on day 4 after resection. All surviving
mice were sacriﬁced and evaluated on day 5.
Assessment of Liver Regeneration
Liver regeneration ratio was calculated as the percentile of
liver weight regained after PHx, as previously described.15
Hepatocyte replication and oval cell proliferation were
studied by immunohistochemistry (IHC). For the hepatocyte
proliferation index, the number of total hepatocytes and
Ki-67epositive hepatocytes were determined in each mouse
liver by counting 10 random periportal ﬁelds at 200
magniﬁcation, and calculating the percentage of replicating
Ki-67epositive hepatocytes. Progenitor (oval) cell prolif-
eration was assessed by the oval cellespeciﬁc marker A6.17
Cells were counted in at least 10 random periportal ﬁelds at
200 magniﬁcation for each mouse liver.
IHC and Immunoﬂuorescence Staining
IHC, H&E, and connective tissue (Sirius Red) staining were
performed in formalin-ﬁxed, parafﬁn-embedded liver sections,
as previously described.18 The primary antibodies used in this
study are summarized in Table 1. The A6 antibody was a kind
gift from Dr. Valentina Factor (NIH, Bethesda, MD). Horse-
radish peroxidaseeconjugated anti-rat or anti-rabbit antibodies
were used for detection, and imageswere captured usingNikon
light microscopy. For immunoﬂuorescence staining, frozen
liver tissues (5 mm thick) were cut andmounted on glass slides.
Primary antibodies were visualized via conjugation to Alexa
Fluor 488 and Alexa Fluor 592 antibodies (Molecular Probes,
Life Technologies, Eugene, OR). Nuclei were counterstained
blue with DAPI. Proliferation of oval cells was assessed by A6
and proliferating cell nuclear antigen (PCNA) double-immu-
noﬂuorescence and double-positive cells were counted in
randomly selected A6-reactive cell clusters at 200 magniﬁ-
cation in 4 to 5 ﬁelds per animal (n Z 5). For ﬂorescence
TUNEL staining, an apoptosis detection kit (Roche Diagnos-
tics, Mannheim, Germany) was used by following the manu-
facturer’s protocol. Images were documentedwith anAxiovert
200M Apotome wide-ﬁeld microscope and Axiovision soft-
ware version 4.6 (Zeiss, Thornwood, NY).Table 1 List of Primary Antibodies for IHC and Immunoﬂuorescence
Primary antibody Type Source
Ki-67 (clone TEC-3) Rat monoclonal Dako (Carpinteria, CA)
Phospho-histone3 Rabbit polyclonal Cell Signaling (Danvers,
MA)
A6 Rat monoclonal Dr. Valentina Factor
(NIH/NCl)
PCNA Rabbit polyclonal Santa Cruz Biotechnology
(Dallas, TX)
PCNA, proliferating cell nuclear antigen.
184Quantitative Real-Time RT-PCR
Relative mRNA levels were quantiﬁed in total liver RNA by
real-time RT-PCR on a LightCycler 1.5 instrument (Roche
Diagnostics) using the TaqMan methodology as we previ-
ously described in detail.19 TaqMan probes (dual-labeled
with 50-FAM and 30-TAMRA) and primers for major pro-
ﬁbrogenic mRNA quantitation were previously designed
and extensively validated.14,19,20
Hepatic Collagen Content
As a quantitative measure of ﬁbrosis, hepatic collagen
deposition was determined biochemically via relative
hydroxyproline content (mg/g liver) in 250 to 300 mg liver
samples from two different lobes after hydrolysis in 6NHCl for
16 hours at 110C as previously described.21 To assess
collagen turnover in the settings of rapid liver mass changes
during regeneration, total hepatic hydroxyproline (mg per
whole liver) was calculated based on individual liver weights
and the corresponding relative hydroxyproline content as
previously described.14,18 Total collagen content in remnant
lobes liver at the time of surgery (day 0) was calculated by
multiplying relative hydroxyproline content determined in
removed lobes during hepatectomy by the weight of the
remnant liver estimated from the weight of removed lobes
(based on the assumption that 70% of the liver is removed and
30% remains). Thereafter, collagen changes were assayed
directly in remnant regenerating liver by determining relative
hydroxyproline in 200 to 300 mg sample, and multiplied by
remnantweight todetermine total hydroxyproline (ugper liver).
Serum levels of transforming growth factor beta (TGFb)1
were assayed using eBioscience Human/Mouse TGF beta1
ELISA kit (#88-8350, eBioscience Inc., San Diego, CA)
according to the manufacturer’s instructions following
additional centrifugation at 10,000  g for 10 minutes at
4C to remove platelets.
Statistical Analysis
Results are expressed at means  SEM. Statistical analyses
were performed using the Student’s t-test, and P values <
0.05 were considered signiﬁcant. Survival data were
analyzed using Kaplan-Meier estimates, and two-way
analysis of variance was performed for the comparison
between the two groups in the time course.
Results
Impaired Liver Regeneration and Poor Survival after
70% Hepatectomy in Mice with Pre-Established
Experimental Liver Fibrosis
After 6 weeks of CCl4 administration, all mice developed
robust liver ﬁbrosis. Total hepatic collagen content
increased fourfold compared to control livers (Figure 1A)ajp.amjpathol.org - The American Journal of Pathology
Progenitors and Fibrotic Liver Regeneration(P < 0.001), and the degree of ﬁbrosis was characterized as
intermediate, based on histological assessment (equivalent
to Metavir score F2/F3) (Figure 1B). Three days after the
last CCl4 injection, a 70% PHx was performed and general
physiological parameters (survival rate, body weight
change, and percentage of regenerated liver weight) were
compared between ﬁbrotic mice and nonﬁbrotic controls.
After hepatectomy, 90.8% of all nonﬁbrotic mice survived
the surgery, whereas mice with ongoing ﬁbrosis showed
a signiﬁcantly reduced survival rate (68.9%; P < 0.05)
(Figure 1C). Fatalities in nonﬁbrotic mice were earlier (days
1 to 3) than in ﬁbrotic mice (days 3 to 6) after hepatectomy,
suggesting that mortality in the ﬁbrotic group was related to
compromised liver regeneration rather than to surgical
complications. Nonﬁbrotic mice lost weight steadily after
PHx from day 1, peaking at day 3 (12.4  4.6%), whereas
ﬁbrotic mice lost more weight over a longer period of time,
peaking at day 4 (19.3  8.3%; P < 0.001) (Figure 1D).
To assess liver regeneration, we monitored restoration of
liverweight at various timepoints after resection.As expected,
nonﬁbrotic PHx mouse liver restored to original weight (38%
increase at day 10 compared to day 1). In comparison, the liver
weights in ﬁbrotic PHx mice increased by only 11% at day 10
compared to day 1 (Figure 1E) (P < 0.001). These ﬁndings
suggest that liver regeneration in ﬁbrotic mice was severely
compromised, even before cirrhosis is established, closely
resembling the poor postresection outcomes in patients with
advanced liver ﬁbrosis and cirrhosis.12
Massive Hepatocyte Death during Liver Regeneration
and Failure of Efﬁcient Hepatocyte Replication in
Fibrotic Mice after Hepatectomy
Next, we aimed to characterize the sequence of events
responsible for deﬁcient liver regeneration in the context of
liver ﬁbrosis. PHx induced a sharp increase in serum ALT at
postoperative day 1 in both normal and ﬁbrotic mice, but
ﬁbrotic mice showed a greater increase (1530  107 IU/L in
ﬁbrotic versus 693  166 IU/L in nonﬁbrotic mice, P <
0.05). Additionally, ﬁbrotic mice showed a second, unex-
pected peak in ALT levels in the late recovery phase between
days 4 and 6, peaking on day 5 (3542 246 IU/L versus 93
65 IU/L in nonﬁbrotic controls, P < 0.0001) (Figure 2A).
Accordingly, serum AST, alkaline phosphatase, and total
bilirubin increased in normal mice only transiently at 1 day,
but peaked in ﬁbrotic mice at a late day 5 time point and
remained elevated at day 10 (Supplemental Table S1).
Careful histological examination revealed that at post-
operative day 5, 71% of ﬁbrotic mice showed focal eosin-
ophilic lesions in the periportal area consisting of large
numbers of dead hepatocytes not found in the ﬁbrotic livers
at earlier (days 1 to 3) or later (days 10 to 14) time points and
at no point in regenerating nonﬁbrotic livers (Figure 2C).
TUNEL staining revealed a high rate of cell apoptosis,
predominantly localizing to areas of focal hepatocyte death,
suggesting that hepatocyte cell death occurred via apoptosisThe American Journal of Pathology - ajp.amjpathol.org(Figure 2C). In ﬁbrotic livers before PHx, TUNELþ cells
were observed in fewer numbers and localized within portal
tracts and ﬁbrotic septa (Figure 2D), whereas normal livers
were virtually TUNEL negative before and 5 days after
hepatectomy. No cholangiocyte death could be detected
histologically (neither in bile ducts nor pseudo ducts of
normal or ﬁbrotic mice, not shown).
After 70% PHx in nonﬁbrotic livers, organ volume and
function was quickly restored via robust replication of almost
all mature hepatocytes, as assessed by immunostaining of
liver sections for the nuclear proliferation marker Ki-67. In
normal livers before surgery, hepatocytes were quiescent.
After PHx, hepatocytes began to proliferate, peaking at day 2
postsurgery (79% Ki-67þ hepatocytes) (Figure 2, B and E).
As expected in ﬁbrotic livers, the baseline hepatocyte
proliferation was elevated before PHx due to ongoing chronic
liver injury and hepatocyte regeneration. However, Ki-67
staining in livers of ﬁbrotic mice was severely blunted with
only 1.8% and 10.5% of hepatocytes proliferating on days 2
and 3, respectively, compared with 7.3% and 79.1% in
normal mice (P < 0.05) (Figure 2, B and E). Moreover, the
rate of Ki-67epositive hepatocytes failed to increase at later
time points (Figure 2B). These ﬁndings suggest that in the
context of the ﬁbrotic microenvironment, liver regeneration
after PHx is severely compromised, primarily by the failure
of hepatocyte replication in early states (days 1 to 3), fol-
lowed by massive focal hepatocyte death at day 5.
Activation of Adult Hepatic Progenitor (Oval) Cells
Follows the Failure of Hepatocyte-Mediated
Regeneration in Fibrotic Liver
When hepatocyte replication is inhibited during regeneration
after PHx, the liver restores its mass via the alternative
pathway of adult hepatic progenitor (oval) cell activation.2 We
hypothesized that failure of hepatocyte replication and
increased cell death after PHx in ﬁbrotic livers may elicit
a similar progenitor response, and analyzed the oval cell
compartment using the progenitor (oval) cell marker A6. In
normal livers, A6-positive staining was observed only within
the portal tracts in quiescent (before PHx) and proliferating
bile ducts (days 5 and 10 post-PHx). In ﬁbrotic mice before
resection, the number of A6-positive cells was markedly
increased and could be observed both in the portal area and
within ﬁbrotic septa extending into the lobule. After PHx in
ﬁbrotic mice, the percentage of A6-positive cells further
increased dramatically from day 5 and peaked at day 10
(threefold increase compared to pre-PHx level and 14-fold
increase compared to normal liver (Figure 3A and B) (P <
0.05) at days 5 and 10 versus normal liver, returning to pre-
PHx levels by day 14. The staining pattern of A6 was asso-
ciated with scattered spindle-shaped cells and irregular-shaped
bile duct-like proliferations (Figure 3A), characteristic of the
pseudoducts formed by proliferating progenitor (oval) cells.
These cells also stained positive for the alternative progenitor
marker pan-cytokeratin (not shown). Sham surgery alone did185
Kuramitsu et alnot elicit progenitor response (Supplemental Figure S1).
Interestingly, increase in circulating TGFb1 levels in ﬁbrotic
(but not normal) mice serum coincided with hepatocyte death
and progenitor (oval) cell expansion at 5 days (Figure 3C).
Evidently, the expansion of progenitor (oval) cells in ﬁbrotic
livers occurred via active proliferation, because nuclei of A6-
immunoreactive progenitor cells were frequently positive for
the proliferation marker PCNA, as demonstrated by double-
immunostaining (Figure 3D). At day 5 post-PHx, at least
one PCNA-positive nucleus was detectable in 52% of
randomly selected A6-reactive cell clusters, with an average of
9.93  2.3% PCNA-positive cells in A6-positive cell
population.
Compromised Fibrotic Liver Regeneration Is Associated
with Increases in Proﬁbrogenic mRNA Expression and
de Novo Collagen Synthesis and Deposition
Given that the mobilization of hepatic progenitors is clini-
cally associated with progressive liver ﬁbrosis,22,23 weFigure 1 Impaired liver regeneration in ﬁbrotic mice, as measured by survival
ﬁbrosis was induced by chronic CCl4 injections for 6 weeks, leading to a fourfold in
via oral gavage. *P < 0.001 versus normal mice receiving mineral oil only. B:
bridging ﬁbrosis. Scale barZ 200 mm. Original magniﬁcation: 100 (left panel);
ﬁbrosis after 70% PHx. Survival rate was calculated using the Kaplan-Meier method
mice (70 of 86. P < 0.05 versus normal mice. D: Loss of body weight after hepate
mice. Each mouse was weighed every day until day 10 post-PHx, results represent
hepatectomy (means  SEM). E: Restoration of liver volume is compromised in ﬁ
liver weight at sacriﬁce by the estimated remnant liver weight, as described in Ma
group), as described in Materials and Methods. **P < 0.0001 compared to norma
186determined collagen deposition and proﬁbrogenic gene
expression in ﬁbrotic livers after PHx. Histological exami-
nation of liver sections at late regeneration (day 10) in mice
with pre-existing ﬁbrosis suggested active collagen deposi-
tion around the proliferating ductular structures with irregular
shape (Figure 4A) that stained positive for A6 (pseudoducts).
To quantitatively assess the activity of ﬁbrogenesis during
liver regeneration, we measured transcript levels of several
well established ﬁbrogenesis activity markers, including
TGFb1, procollagen a 1(I), a-smooth muscle actin (a-SMA),
and tissue inhibitor of metalloproteinases-1 (TIMP-1). All of
these markers increased several-fold and peaked at day 5,
whereas nonﬁbrotic mice showed low proﬁbrogenic mRNA
levels throughout regeneration after PHx (Figure 4B). Inter-
estingly, this dramatic increase in proﬁbrogenic transcripts,
which can be ascribed mainly to activated hepatic stellate
cells and myoﬁbroblasts, coincided with a similar increase in
TGFb2 and integrin b6 (Figure 4B). Both molecules are
expressed speciﬁcally by activated biliary epithelium (reac-
tive cholangiocytes and progenitor cells) in liver ﬁbrosis,20rate, body weight, and restoration of liver volume after PHx. A: Robust liver
crease in total hepatic collagen content (mg per liver) in mice receiving CCl4
Connective tissue staining (Sirius red) showing histological signs of early
200 (right panel). C: Reduced survival in mice with pre-established liver
and was 90.8% in normal mice (137 of 144) compared to 68.9% in ﬁbrotic
ctomy is more signiﬁcant in ﬁbrotic mice after PHx. P < 0.05 versus normal
percent change in individual mouse body weight versus body weight before
brotic livers. Regeneration ratio was assessed by dividing each regenerated
terials and Methods. Data are expressed as means  SEM (6 to 12 mice per
l mice at corresponding time points.
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Figure 2 Repressed hepatocyte replication and
increased hepatocyte cell death in ﬁbrotic mice
after PHx. A: Marked increase in serum trans-
aminases at late stages (4 to 6 days) after PHx
suggests massive hepatocyte death in mice with
pre-established ﬁbrosis. Serum ALT levels were
monitored over time in normal and ﬁbrotic mice
after PHx. Means  SEM (n Z 6 to 12 mice per
group). *P< 0.01 at day 1 and **P< 0.0001 at day
5 versus normal mice. B: Quantiﬁcation of Ki-67þ
nuclei of hepatocytes after PHx. Hepatocytes were
identiﬁed by typical morphological appearance and
Ki-67þ nuclei were counted in 10 high-power ﬁelds
in at least ﬁve individual mice per time point. Each
bar represents means  SEM of the number of
positive hepatocytes and high-power ﬁeld. *P <
0.05, **P < 0.0001 versus normal mice. C: H&E
staining of liver samples at selected time points
after hepatectomy. Arrow indicates eosinophilic
area of vanishing dead hepatocytes in periportal
areas. Original magniﬁcation: 200 (left and
middle); 400 (right). Scale bar Z 200 mm. Left
image, day 0; middle and right images, day 5. D:
TUNEL staining notably increased at day 5 after PHx
in ﬁbrotic livers. and localize within and at the
interface areas of hepatocytic death (arrows),
suggesting apoptotic cell death mechanism. E:
Hepatocytes in ﬁbrotic mice fail to replicate after
PHx. Representative images from liver sections
stained with proliferation marker Ki-67 show low
replicative activity in hepatocytes in ﬁbrotic
(upper row) versus nonﬁbrotic livers (lower row)
at day 2 after hepatectomy. Arrows indicate posi-
tive Ki-67 staining in hepatocyte nuclei. Scale bar
Z 100 mm.
Progenitors and Fibrotic Liver Regenerationcells that are considered major drivers of biliary-type
ﬁbrosis.11,20,24
Next, we aimed to determine whether increased proﬁ-
brogenic mRNA resulted in collagen synthesis and deposi-
tion, and we analyzed the quantitative changes in hepatic
collagen protein content after PHx in mice with pre-existing
ﬁbrosis. Because signiﬁcant changes in liver mass may
occur rapidly compared to the relatively slow process of
ﬁbrotic tissue deposition, total collagen content (per wholeThe American Journal of Pathology - ajp.amjpathol.orgorgan) was measured in addition to relative collagen levels
(mg/100 mg of tissue) to accurately assess changes in
ﬁbrotic liver.14,18 Collagen quantitation in resected lobes
and in the regenerating remnant liver revealed two things:
a drop in relative hydroxyproline level by 44% at day 1
(reﬂecting dilution of ﬁbrous tissue due to rapid gain in liver
volume), which increased again starting at day 5 to almost
the pre-PHx levels (71% and 88% of average pre-PHx
values at days 5 and 10, respectively) (P < 0.05); and no187
Figure 3 Massive activation of hepatic progenitor (oval) cell compartment in late stages of regeneration in ﬁbrotic livers. A: Expansion of hepatic
progenitor (oval) cells in portal areas starting from day 5 after PHx in ﬁbrotic liver. Representative images from liver sections stained for oval cell marker A6 at
selected time points in normal and ﬁbrotic mice after hepatectomy. Upper panel: Normal liver without hepatectomy at days 0, 5, and 10 after PHx. Lower
panel: Fibrotic liver at 0, 5, and 10 days after hepatectomy. Arrow indicates positive staining. Original magniﬁcation, 100. Scale bar Z 200 mm. B:
Quantiﬁcation of A6þ oval cells numbers after PHx in normal (open bars) versus ﬁbrotic (closed bars). Ten randomly chosen portal vein areas were assessed in
sections from ﬁve individual mice (means  SEM of A6þ cell counts per high-power ﬁelds). *P < 0.001, **P < 0.0001 versus livers without hepatectomy. C:
Serum TGFb1 levels after PHx differ signiﬁcantly in normal and ﬁbrotic mice and increase dramatically at day 5 in ﬁbrotic mice. Serum TGFb1 was determined
using an eBioscience Human/Mouse TGF beta1 ELISA kit , as described in Materials and Methods. D: A6þ progenitor (oval) cells actively proliferate in ﬁbrotic
liver after hepatectomy. Representative image is shown (5 days post-PHx, ﬁbrotic) of double-immunoﬂuorescence staining of liver samples for progenitor cell
and proliferation markers that frequently colocalize (arrows). PCNA, green, nuclear proliferation marker; A6, red, cytoplasmic oval cell marker; DAPI, blue,
nuclei. Original magniﬁcation, 200. Scale bar Z 50 mm.
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Figure 4 PHx elicits delayed, additive proﬁbrogenic response in ﬁbrotic mice. A: Connective tissue staining (Sirius Red) demonstrates reactive collagen
deposition around duct-like proliferations (arrows). Representative liver section of ﬁbrotic mice 10 days after PHx. Oval cell marker A6 staining labels these
ductular structures of the same area. B: Dramatic increase in proﬁbrogenic expression which peaks 5 days after PHx in regenerating ﬁbrotic liver (black bars) but
not in normal liver (white bars). Liver samples were collected at selected time points after hepatectomy, and hepatic mRNA levels of procollagen a1(I) (collagen),
a-SMA, TIMP-1, TGFb1, and TGFb2, and integrin b6 were analyzed by real-time PCR. Results represent means SEM expressed as fold change over normal mouse
controls from 4 to 6 mice per group. *P < 0.05 versus ﬁbrotic livers before hepatectomy; **P < 0.05 versus normal liver at corresponding time points.
Progenitors and Fibrotic Liver Regenerationchange in total collagen content in the remaining lobe at
day 1, but a signiﬁcant increase starting from day 5
(reaching 133% and 160% of average pre-PHx values at
days 5 and 10, respectively) (P < 0.05), as summarized in
Table 2. This indicates that the proﬁbrogenic response at
day 5 resulted in de novo collagen synthesis and deposition.
The ﬁbrogenic process triggered by PHx can be deﬁned as
severe, because the actual rate of collagen deposition
during regeneration (average 15.41 mg of hydroxyproline
per day per liver) is comparable to the most aggressiveThe American Journal of Pathology - ajp.amjpathol.orgCCl4-induced ﬁbrosis
14 (average 15.24 mg of hydroxypro-
line per day per liver, assuming that collagen deposition is
a linear process) (Figure 1A). In contrast, total collagen
content increased only modestly, and relative collagen
content remained below pre-hepatectomy levels in normal
mice (Table 2). These ﬁndings suggest that activation of
oval cell-mediated regeneration in ﬁbrotic livers is associ-
ated with a pronounced ﬁbrogenic response comparable to
levels during active chronic ﬁbrosis. This in turn results in
rapid de novo deposition of ﬁbrotic tissue in the remnant189
Table 2 Collagen Content Increases in the Remnant Liver after 70% PHx in Fibrotic Mice, Indicating Active Fibrogenesis and de Novo
Collagen Deposition
Groups
Relative collagen content (mg/100 mg) Total collagen content (mg/liver)
Before surgery* After 70% PHx Before surgeryy After 70% PHx
Day 1 (F) 50.98  4.64 28.84  3.1z 236.7  14.51 229.2  26.35
Day 5 (F) 51.32  2.64 36.40  3.34z 251.1  17.66 334.7  18.83z
Day 10 (F) 49.97  4.75 43.79  6.46 259.0  31.37 413.1  30.45z
Day 1 (N) 18.01  0.44 13.22  0.68z 63.46  2.75 75.89  4.55
Day 5 (N) 18.13  0.34 11.78  0.32z 65.35  3.4 103.9  5.07z
Day 10 (N) 18.73  0.51 13.54  0.78z 65.44  2.6 150.6  11.04z
Collagen content was determined biochemically via hepatic hydroxyproline in the resected lobe of each individual mouse at the time of surgery and in the
remnant liver after regeneration for 1, 5, and 10 days (n Z 6 to 8 per group). Both relative (per 100 mg of liver) and total collagen content (per whole
remaining liver) increased signiﬁcantly starting from day 5 in ﬁbrotic mice (F), suggesting signiﬁcant de novo collagen synthesis and deposition occurs after
partial hepatectomy (PHx) in mice with pre-existing ﬁbrosis. In normal mice (N) relative collagen remained below pre-PHx levels up to day 10, whereas total
collagen in remnant liver increased modestly.
*Relative collagen levels determined in removed 70% of the liver at the time of surgery (day 0).
yEstimated in remaining 30% of liver based on corresponding values in resected lobes.
zP < 0.05 compared to pre-PHx levels in corresponding group (Student’s t-test).
Kuramitsu et alliver after PHx, which is likely to further impair hepatic
regeneration.Manipulation of Hepatic Progenitor Cells Modulates
the Proﬁbrogenic Response and Fibrotic Liver
Regeneration in Vivo
Our ﬁndings thus far have suggested that oval cell-mediated
liver regeneration is activated in ﬁbrotic mice, and progenitor
cell expansion is spatiotemporally associated with adverse
events during impaired regeneration of the ﬁbrotic liver,
including an increase in serum ALT and ampliﬁed ﬁbro-
genesis. To test whether activation of the progenitor cell
compartment modulates ﬁbrotic liver regeneration and clin-
ical outcomes after resection, we took advantage of the
recently identiﬁed TWEAK pathway to experimentally
manipulate the mitogenic oval cell response.25,26 We treated
ﬁbrotic mice after 70% hepatectomy with either the oval cell
mitogen TWEAK administered exogenously to amplify the
progenitor response, or TWEAK-neutralizing antibody to
inhibit the progenitor reaction. We evaluated parameters of
regeneration, liver function, and ﬁbrogenesis 5 days post-
resection, when most of the adverse changes in ﬁbrotic mice
peaked. Histological examination revealed signiﬁcant
expansion of duct-like structures positive for the oval-cell
marker A6 in the TWEAK-treated group. Conversely,
progenitor (oval) cell proliferation was dramatically reduced
in the group that received TWEAK-neutralizing antibody
(Figure 5A). Furthermore, proﬁbrogenic gene expression
was signiﬁcantly down-regulated at day 5 for all studied
mRNAs (TGFb1, procollagen I, a-SMA, TIMP-1, TGFb2,
integrin b6) in the group treated with anti-TWEAK mono-
colonal antibody (Figure 5D). Moreover, regeneration ratio
was improved and serum ALT levels were normalized in the
anti-TWEAK group (P < 0.05) compared to the isotype
controls (Table 3 and Supplemental Table S2). The group190treated with anti-TWEAK antibody also showed an early
trend to lower relative hepatic collagen levels at 5 days and
histologically less severe ﬁbrosis (Table 3 and Figure 5B). In
contrast, mice treated with the oval cell mitogen TWEAK
showed signiﬁcantly upregulated procollagen I, TGFb2, and
integrin b6 transcripts, whereas TGFb1, a-SMA, and TIMP-
1 remained elevated and did not change compared to the
isotype antibody controls. Serum ALT was not changed by
exogenous TWEAK treatment. Importantly, blocking
TWEAK by antibody stimulated hepatocyte replication (by
85% compared to isotype controls (PZ 0.0013) (Figure 5C
and Table 3), whereas administration of TWEAK resulted in
predominant replication of progenitor (oval) cells within
ductular structures (Figure 5C and Table 3). Taken together,
these data indicate that activation of the progenitor (oval) cell
compartment not only coincides with the failure of ﬁbrotic
liver regeneration, but also contributes functionally to it, via
ampliﬁcation of the proﬁbrogenic response after resection.Discussion
Rigorous mechanistic understanding of the failure of ﬁbrotic
liver to regenerate (as opposed to the almost unlimited
regenerative capacity of normal livers) is critical toward the
development of safe and targeted ways to improve liver
resection outcomes in patients with chronic liver disease and
cirrhosis. Although normal liver regeneration has been
extensively studied for the past few decades, surprisingly
little is known about the pathophysiology of ﬁbrotic liver
regeneration.
Here, we performed a comprehensive characterization of
liver regeneration after 70% partial hepatectomy in normal
mice and those with pre-established experimental ﬁbrosis.
This analysis revealed profound, characteristic, and in some
instances even unexpected differences between regeneration
on normal and ﬁbrotic livers that can explain much of theajp.amjpathol.org - The American Journal of Pathology
Figure 5 Manipulation of hepatic progenitor
expansion during regeneration modulates ﬁbro-
genic response and ﬁbrotic liver regeneration.
Experimental manipulation of the hepatic progen-
itor (oval) cell proliferative response post-PHx was
effectively achieved in both directions: robust
increase in A6þ progenitor cells in animals receiving
TWEAK-Fc injections (TWEAK, 75 mg per mouse,
nZ 10), as well as dramatic inhibition of the oval
cell response in mice receiving neutralizing anti-
TWEAK antibody (a-TWEAK, 75 mg per mouse,
n Z 6) compared to mice injected with irrelevant
isotype IgG (P1.17, 75 mg per mouse, n Z 8). A:
Representative images from liver sections stained
with oval cell marker A6 IHC in ﬁbrotic mice at day 5
after PHx. Connective tissue (Sirius Red) staining
(B) and proliferation marker (Ki-67) IHC (C) of livers
from ﬁbrotic mice treated with isotype control
antibody (Iso), TWEAK-Fc (TWEAK), or anti-TWEAK
antibody (anti-TWEAK) 5 days after 70% PHx. Note
increased proliferation predominantly of hepato-
cytes in anti-TWEAK group and mostly within duct-
ular structures in TWEAK-treated mice (quantiﬁed in
Table 3). C: Representative images shown. Original
magniﬁcation, 200. D: Manipulation of oval cell
proliferation modulates proﬁbrogenic response
associated with ﬁbrotic liver regeneration. Signiﬁ-
cant decrease in proﬁbrogenic mRNA expression
5 days after PHx in mice receiving TWEAK-
neutralizing antibody (anti-TWEAK, 75 mg per
mouse). Hepatic mRNA level of TGFb1, COL1A1
(procollagen type 1), a-SMA, TIMP-1, TGFb2, and
integrin b6 were analyzed by real-time RT-PCR. Each
bar represents means  SEM expressed as fold
change over normal controls (nZ 6 to 8 per group).
*P< 0.05, **P< 0.01 compared to isotype control
group (P1.17).
Progenitors and Fibrotic Liver Regenerationcompromised, pathological regeneration of the ﬁbrotic liver.
In striking contrast to normal liver regeneration, ﬁbrotic
liver showed: i) failure of appropriate parenchymal cell
replication, as evidenced by an eightfold lower rate of
hepatocytes positive for proliferation markers; ii) signiﬁcant
cell death in late stages of regeneration (peak at day 5) as
demonstrated by focal hepatocyte apoptotic cell death and
increased ALT levels; iii) an association with a marked
progenitor (oval) cell expansion, as evidenced by a 14-fold
increase in A6-positive cells at day 10; and iv) a severeThe American Journal of Pathology - ajp.amjpathol.orgﬁbrogenic response, as reﬂected by a dramatic upregulation
of multiple proﬁbrogenic genes resulting in further excess
collagen deposition. We propose that these pathophysio-
logical features comprise the pathological sequence of
events that lead to impaired restoration of liver volume and
function in hepatectomized ﬁbrotic mice.
Impairment of hepatocyte replication after PHx in the
ﬁbrotic rat liver was described earlier, consistent with our
ﬁndings (Figure 2E), and proposed to be linked to a failure of
cyclin D induction.27 Accordingly, stimulation of hepatocyte191
Table 3 Liver Regeneration, Serum ALT, and Hepatic Hydroxyproline Levels in Fibrotic Mice Treated with TWEAK and Anti-TWEAK after 70%
Hepatectomy
Group Regeneration ratio (%) ALT (U/L) Collagen (ug/100 mg)
Proliferation (Ki-67þ cells/
high-power ﬁelds)
Hepatocytes Ductular cells
P1.71 49.69  4.54 306  88 41.14  3.05 9.66  0.87 10.33  1.24
TWEAK 50.80  4.74 153.6  60.6 44.50  2.85 9.15  1.21 24.47  2.88*
Anti-TWEAK 62.89  2.58* 48.5  23.3* 33.95  2.35 17.76  1.14* 3.80  0.29*
Regeneration ratio was assessed by calculating each regenerated liver weight at the time of sacriﬁce (day 5) as percentage of pre-resection liver weight
(estimated based on weight of resected lobes). Serum alanine aminotransferase (ALT) levels and hepatic collagen (as hydroxyproline content) were measured
at sacriﬁce, as described in Materials and Methods (nZ 6 to 10 mice per group). Cell proliferation was assessed by quantiﬁcation of Ki-67þ hepatocytes and Ki-
67þ ductular cells (see staining in Figure 5, C and D). Ten random high-power ﬁelds at 200 magniﬁcation were counted in 4 to 5 mice per group. Data are
expressed as means  SEM.
*P < 0.05 versus P1.71 control group.
Kuramitsu et alreplication with hepatocyte growth factor gene therapy
accelerated regeneration after hepatectomy in ﬁbrotic liver.28
However, focal hepatocyte cell death with a marked increase
in serum transaminase levels at late stages of regeneration
(days 4 to 6) in ﬁbrotic liver (Figure 2, A and C) has not been
described before and appears to be relevant to the increased
mortality after hepatectomy in patients with ﬁbrosis,12 as also
found in our experimental model (Figure 1C). It is tempting
to speculate that massive hepatocyte death at day 5 may
directly trigger the progenitor response in our system, which
appears to occur via apoptosis (Figure 2D).29 Interestingly,
hepatocyte death was paralleled by an increase in serum
TGFb1 levels in ﬁbrotic mice (Figure 3C), which in contrast
was only transiently increased in normal mice at day 1 post-
PHx. Because anti-proliferative and pro-apoptotic properties
of TGFb1 in hepatocytes [but not progenitor (oval) cells] are
well documented,30 it is plausible that dysregulation of
TGFb1 may be responsible for the shift from normal
hepatocyte-driven regeneration to oval-cell mediated regen-
eration in ﬁbrotic liver. Further studies are necessary to
elucidate the precise molecular mechanism underlying
aberrant TGFb1 responses, hepatocyte death, and the
(ﬁbrogenic) progenitor activation during pathophysiological
regeneration of the ﬁbrotic liver.
Importantly, we show for the ﬁrst time that ﬁbrotic liver
regeneration is driven mostly progenitor (oval) cell, which is
in sharp contrast to mature hepatocyte-mediated regenera-
tion of the normal liver.1,2,7 Interestingly and unexpectedly,
regeneration of ﬁbrotic liver in the late stages (days 3 to 5)
was associated with a pronounced increase in several pro-
ﬁbrogenic transcripts above levels in active ongoing ﬁbrosis
(eg, at the time of surgery that corresponds to peak ﬁbrosis
after 6 weeks of CCl4 treatment), such as TGFb1, a-SMA,
TIMP-1, TGFb2, and integrin b6.11 Timing of this severe
ﬁbrogenic response coincided with remarkable oval cell
activation starting at day 5 (Figure 3B) and was followed by
ﬁbrotic matrix deposition around progenitor cell-like duct-
ular proliferations (Figure 4A and Table 2). Progenitors are
postulated to give rise to reactive cholangiocytes in chronic
liver disease that secrete multiple soluble proﬁbrogenic192factors acting on hepatic stellate cells and myoﬁbroblasts in
a paracrine fashion.11 Moreover, reactive cholangiocytes
overexpress integrin avb6, which correlates with ﬁbrosis
progression in human and experimental liver disease and
functionally contributes to progression of experimental
biliary liver ﬁbrosis.20,24 Removal of these activated chol-
angiocytes via apoptosis is instrumental for biliary ﬁbrosis
reversal after surgical restoration of bile ﬂow,18 further
underscoring the important proﬁbrogenic role of the
progenitor and cholangiocyte cell lineage.
The functional requirement of a progenitor response for
ﬁbrogenesis has not been established to date and is a matter of
continued debate.31 Recent animal studies (albeit descriptive)
have questioned the role of the oval cell response in driving
ﬁbrosis.32 Moreover, progenitor cell-mediated regeneration
may represent a beneﬁcial compensatory reserve mechanism
when normal hepatocyte replication is impaired.2,33 There-
fore, we sought to establish the functional role for the acti-
vation of the progenitor (oval) cell compartment during
ﬁbrotic liver regeneration by direct manipulation of progen-
itor cell proliferation after PHx in ﬁbrotic mice. Adminis-
tration of a TWEAK-blocking monoclonal antibody after
hepatectomy efﬁciently inhibited the progenitor cell
response, as expected,26 and as evidenced by a markedly
reduced number of A6-positive cells, inhibition of prolifer-
ation marker Ki-67 in ductular cells, and normalized serum
ALT levels, and this signiﬁcantly reduced the proﬁbrogenic
response, as reﬂected by ﬁbrogenic transcript levels (Figure 5
and Table 3). In contrast, administration of the oval cell
mitogen recombinant TWEAK-Fc protein25 post-PHx
strongly stimulated progenitor proliferation and the proﬁ-
brogenic mRNA response in the regenerating liver (Figure 5).
TGFb2, integrin b6, and procollagen a1(I) were most strik-
ingly upregulated, proﬁbrogenic molecules that are associ-
ated with reactive cholangiocyte and progenitor-driven
ﬁbrogenesis,19,20,34 further supporting that this was indeed
a progenitor cell-driven ﬁbrogenic response. Interestingly,
although ductular cell proliferation was suppressed in mice
with TWEAK inhibition, the hepatocyte replication rate was
signiﬁcantly increased, shifting the proliferative responseajp.amjpathol.org - The American Journal of Pathology
Progenitors and Fibrotic Liver Regenerationfrom progenitor-driven to the hepatocyte-driven regeneration
(Figure 5C and Table 3). To our knowledge, this is the ﬁrst
direct experimental evidence that hepatic progenitor activa-
tion is driving ﬁbrogenesis in vivo. This concept was
proposed based on early histological observations35 and later
corroborated in correlative studies with human liver
samples,22,23 but thus far lacked functional proof.31 Although
we cannot entirely rule out that TWEAK may act on several
cell types in the liver, the most pronounced (and reported
in vivo) effect of overexpression or exogenous administration
of TWEAK is oval cell and progenitor proliferation.25,26
In summary, we have established a sequence of patho-
logical events associated with compromised ﬁbrotic liver
regeneration. Based on our results, we propose a vicious
circle model in which failure of hepatocyte replication and
death during ﬁbrotic liver regeneration activates the reserve
progenitor (oval) cell compartment, which in turn elicits
a severe ﬁbrogenic response and further compromises
hepatocyte-mediated liver regeneration in the ﬁbrotic
microenvironment. Finally, we demonstrate that therapeutic
inhibition of progenitor cell activation via the TWEAK
pathway attenuates the ﬁbrogenic response, and improves
liver function and regeneration. Therapies that target the
progenitor cell may prove to be a novel and promising
strategy to improve surgical outcomes in patients with liver
ﬁbrosis undergoing PHx.
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